GSK2643943A是一种靶向USP20的去泛素化酶（DUB）抑制剂，GSK2643943A通过抑制USP20/Ub-Rho（IC50=160nM）的活性来阻断蛋白质-泛素键的裂解。
Cas No.:2449301-27-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
GSK2643943A is a deubiquitinase (DUB) inhibitor targeting USP20. GSK2643943A blocks the cleavage of protein-ubiquitin bonds by inhibiting USP20/Ub-Rho (IC50=160nM)[1-2]. GSK2643943A can be used in research related to cancers such as oral squamous cell carcinoma (OSCC) and T-cell acute lymphoblastic leukemia (T-ALL)[3-4].
In vitro, A549 and NCI-H460 cells were treated with GSK2643943A (160nM) for 24-72 hours. GSK2643943A reduced cytoplasmic PTEN protein levels and increased PTEN ubiquitination. When co-treated with pcDNA3.1-OTUD5, GSK2643943A reversed the inhibitory effects of OTUD5 overexpression on cell proliferation, migration, and invasion[5]. HEK293FT cells were incubated with GSK2643943A (1-5μM) for 12 hours. GSK2643943A led to elevated levels of ubiquitination of the endoplasmic reticulum autophagy receptor RETREG1[6].
In vivo, GSK2643943A (15mg/kg) was administered via intraperitoneal injection once daily for a total of 10 times (5 consecutive days, followed by a 2-day interval, then another 5 consecutive days) to NSG mice inoculated with T-ALL cells. GSK2643943A significantly prolonged the survival of the mice[7]. GSK2643943A (5mg/kg or 2.5mg/kg) was administered via intraperitoneal injection once daily for 6 or 9 consecutive days to mice bearing SCC9 or SCC7 tumors. The combination treatment of GSK2643943A and the oncolytic virus T1012G significantly inhibited tumor growth in mice[8].
References:
[1] Qin B, Zhou L, Wang F, et al. Ubiquitin-specific protease 20 in human disease: Emerging role and therapeutic implications. Biochem Pharmacol. 2022 Dec;206:115352.
[2] Jiang X, Zhao B, Wang T, et al. USP20-Driven Cholesterol Metabolism Links Inflammatory Signaling to Malignancy and Stromal Coevolution in Pancreatic Cancer. Cancer Res. 2026 Feb 2;86(3):712-729.
[3] Li WT, Jin X, Song SJ, et al. Blocking SLC7A11 attenuates the proliferation of esophageal squamous cell carcinoma cells. Anim Cells Syst (Seoul). 2024 May 11;28(1):237-250.
[4] Böhm K, Schulze-Niemand E, Kähne T, et al. Synthesis and structure-activity relationships of USP48 deubiquitinylase inhibitors. Arch Pharm (Weinheim). 2023 Jul;356(7):e2200661.
[5] Li X, Lu B, Zhang L, et al. Mechanism of OTUD5 in non-small cell lung cancer cell proliferation, invasion, and migration. Bosn J Basic Med Sci. 2022 Oct 23;22(6):901-911.
[6] Zhang M, Wang Z, Zhao Q, et al. USP20 deubiquitinates and stabilizes the reticulophagy receptor RETREG1/FAM134B to drive reticulophagy. Autophagy. 2024 Aug;20(8):1780-1797.
[7] Xu L, Zhang Z, Yu J, et al. USP20 as a super-enhancer-regulated gene drives T-ALL progression via HIF1A deubiquitination. Acta Pharm Sin B. 2025 Sep;15(9):4751-4771.
[8] Lu R, Wu G, Chen M, et al. USP18 and USP20 restrict oHSV-1 replication in resistant human oral squamous carcinoma cell line SCC9 and affect the viability of SCC9 cells. Mol Ther Oncolytics. 2021 Nov 11;23:477-487.
GSK2643943A是一种靶向USP20的去泛素化酶（DUB）抑制剂，GSK2643943A通过抑制USP20/Ub-Rho（IC50=160nM）的活性来阻断蛋白质-泛素键的裂解[1-2]。GSK2643943A可用于口腔鳞状细胞癌（OSCC）和T细胞急性淋巴细胞白血病（T-ALL）等癌症的相关研究[3-4]。
在体外，GSK2643943A（160nM）处理A549和NCI-H460细胞24-72小时。GSK2643943A降低了细胞质PTEN的蛋白水平，同时增加了PTEN的泛素化水平；当与pcDNA3.1-OTUD5共处理时，GSK2643943A逆转了OTUD5过表达对细胞增殖、迁移和侵袭的抑制作用[5]。GSK2643943A（1-5μM）孵育HEK293FT细胞12小时。GSK2643943A导致细胞的内质网自噬受体RETREG1泛素化水平升高[6]。
在体内，GSK2643943A（15mg/kg）通过腹腔注射于接种了T-ALL细胞的NSG小鼠，每天给药一次、共计10次（连续注射5天后，时隔2天后再连续注射5天）。GSK2643943A显著延长了小鼠的生存期[7]。GSK2643943A（5mg/kg或2.5mg/kg）通过腹腔注射于携带SCC9或SCC7肿瘤的小鼠，每天给药一次、连续6天或9天。GSK2643943A联合溶瘤病毒T1012G的治疗显著抑制了小鼠的肿瘤生长[8]。
| Cell experiment [1]: | |
Cell lines | Human Embryonic Kidney 293 cells stably expressing the SV40 large T antigen (HEK293FT) |
Preparation Method | HEK293FT culture methods within the document indicate cells were maintained in DMEM supplemented with 10% fetal bovine serum at 37°C under 5% CO₂. The cells were treated with GSK2643943A (1-5μM) for 12h. |
Reaction Conditions | 1-5μM; 12h. |
Applications | Treatment with GSK2643943A elevated levels of RETREG1 ubiquitination compared to the control. |
| Animal experiment [2]: | |
Animal models | NSG mice (NOD scid gamma mice) |
Preparation Method | NSG mice were injected via the tail vein with J.gamma1 T-ALL cells expressing firefly luciferase. The experimental group then received intraperitoneal injections of GSK2643943A (15mg/kg). |
Dosage form | 15mg/kg; i.p.; once daily for 10 times (After continuous injection for 5 days, continue injection for another 5 days after a 2-day interval). |
Applications | Treatment with GSK2643943A significantly prolonged survival and significantly reduced the bioluminescence signal (indicating inhibition of tumor growth) in the T-ALL mouse model. |
References: | |
| Cas No. | 2449301-27-1 | SDF | |
| Canonical SMILES | FC1=CC=CC(/C=C/C2=CC(NC(N)=C3C#N)=C3C=C2)=C1 | ||
| 分子式 | C17H12FN3 | 分子量 | 277.3 |
| 溶解度 | DMSO : ≥ 125 mg/mL (450.78 mM);Water : < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6062 mL | 18.031 mL | 36.062 mL |
| 5 mM | 721.2 μL | 3.6062 mL | 7.2124 mL |
| 10 mM | 360.6 μL | 1.8031 mL | 3.6062 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet